Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 262Specimen Handling 253pembrolizumab 230Cyclophosphamide 216Radiotherapy 204Nivolumab 168Cisplatin 161Carboplatin 145Biopsy 144Radiosurgery 128fludarabine 123Blood Specimen Collection 116Gemcitabine 111Paclitaxel 107Surveys and Questionnaires 106Standard of Care 102venetoclax 94Dexamethasone 93Bevacizumab 92Radiation 87Rituximab 81Capecitabine 80Cytarabine 79Oxaliplatin 77Drug Therapy 75Doxorubicin 75Ipilimumab 73durvalumab 70fludarabine phosphate 69atezolizumab 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × dupilumab × 90 days × Clear all
NCT06637306 2026-05-14

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase EARLY_PHASE1 Recruiting
15 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07277322 2026-04-29

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

Icahn School of Medicine at Mount Sinai

Phase 1/2 Not yet recruiting
24 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡